XBRANE.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:29):

Stats
Today's Volume	20.97M
Average Volume	17.07M
Market Cap	553.40M
EPS	SEK0 ( 2024-02-26 )
Next earnings date	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.280
ATR14	SEK0.00200 (0.57%)

Volume Correlation

Long: -0.20 (neutral)

Short: -0.81 (strong negative)

Signal:(42.738) Neutral

Xbrane Biopharma AB Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xbrane Biopharma AB Correlation - Currency/Commodity

-0.86
( strong negative )

-0.77
( moderate negative )

0.00
( neutral )

0.84
( strong )

Xbrane Biopharma AB Financials

Annual	2023
Revenue:	SEK238.73M
Gross Profit:	SEK13.96M (5.85 %)
EPS:	SEK-1.530

Q4	2023
Revenue:	SEK66.89M
Gross Profit:	SEK4.24M (6.33 %)
EPS:	SEK-0.600

Q3	2023
Revenue:	SEK58.89M
Gross Profit:	SEK4.15M (7.05 %)
EPS:	SEK-0.310

Q2	2023
Revenue:	SEK51.10M
Gross Profit:	SEK11.47M (22.44 %)
EPS:	SEK-0.370

Financial Reports:

No articles found.

Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.